Current Oncology Reports

, 16:365 | Cite as

Endoglin for Targeted Cancer Treatment

  • Lee S. RosenEmail author
  • Michael S. Gordon
  • Francisco Robert
  • Daniela E. Matei
Evolving Therapies (R Bukowski, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Evolving Therapies


Endoglin is a homodimeric cell membrane glycoprotein receptor for transforming growth factor β and bone morphogenetic proteins. Endoglin is essential for angiogenesis, being densely expressed on proliferating endothelial cells and upregulated during hypoxia. Its expression is implicated in development of resistance to vascular endothelial growth factor (VEGF) inhibition. TRC105 is an antibody that binds endoglin and prevents endothelial cell activation. Targeting endoglin and the VEGF pathway concurrently improves treatment in vitro and appears to reverse resistance to bevacizumab in some refractory cancer patients. Randomized trials are under way to assess the clinical benefit of adding TRC105 therapy to bevacizumab therapy. Further trials are under way to assess the activity of TRC105 with small-molecule inhibitors of the VEGF pathway in renal cell carcinoma, hepatocellular carcinoma, and soft tissue sarcoma. Stratification of soft tissue sarcomas based on endoglin expression levels is proposed to identify patients most likely to benefit from TRC105 treatment. The development of a TRC105 antibody–drug conjugate is also described.


Endoglin CD105 TRC105 Angiogenesis Vascular endothelial growth factor resistance Antibody–drug conjugate Hypoxia Bone morphogenic protein Transforming growth factor β Antibody Radioimmunoconjugate Renal cell cancer Sarcoma Glioblastoma Prostate cancer Hepatocellular cancer 


Compliance with Ethics Guidelines

Conflict of Interest

Lee S. Rosen received funding from Tracon Pharma for a clinical trial.

Michael S. Gordon, Francisco Robert, and Daniela E. Matei declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931–4.PubMedGoogle Scholar
  3. 3.
    Hurwitz H, Fehrehbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Friedman HS, Prados MD, Wen P, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Joulain F, Proskorovsky I, Allegra C, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer. 2013;109:1735–43.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Motzer RJ, Hutson TE, Tonczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.PubMedCrossRefGoogle Scholar
  15. 15.
    van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.PubMedCrossRefGoogle Scholar
  16. 16.
    Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010;21:21–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Bergers G. Hanahan.D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Haruta Y, Seon BK. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci U S A. 1986;83:7898–902.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol. 1988;141:1925–33.PubMedGoogle Scholar
  20. 20.
    Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Paauwe M, ten Dijke P, Hawinkels LJ. Endoglin for tumor imaging and targeted cancer therapy. Expert Opin Ther Targets. 2013;17:421–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res. 1995;1:1623–34.PubMedGoogle Scholar
  24. 24.
    She X et al. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer. 2004;108(2):251–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Li C, Issa R, Kumar P, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003;116:2677–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Sánchez-Elsner T, Botella LM, Velasco B, et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem. 2002;277:43799–808.PubMedCrossRefGoogle Scholar
  27. 27.
    van Laake LW, van den Driesche S, Post S, et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation. 2006;114:2288–97.PubMedCrossRefGoogle Scholar
  28. 28.
    Lenato GM, Guanti G. Hereditary haemorrhagic telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des. 2006;12:1173–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Sabba C, Pasculli G, Lenato GM, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. J Thromb Haemost. 2007;5:1149–57.PubMedCrossRefGoogle Scholar
  30. 30.
    Rokhlin OW, Cohen MB, Kubagawa H, et al. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol. 1995;154:4456–65.PubMedGoogle Scholar
  31. 31.
    Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999;59:856–61.PubMedGoogle Scholar
  32. 32.
    Vo MN, Evans M, Leitzel K, et al. Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy. Breast Cancer Res Treat. 2008;119:767–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 2001;7:3410–5.PubMedGoogle Scholar
  34. 34.
    El-Gohary YM, Silverman JF, Olson PR, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol. 2007;127:572–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Svatek RS, Karam JA, Roehrborn CG, et al. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res. 2008;14:3362–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Li C, Gardy R, Seon BK, et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003;88:1424–31.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Romani AA, Borghetti AF, Del Rio P, et al. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol. 2006;93:446–55.PubMedCrossRefGoogle Scholar
  38. 38.
    Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:469–74.PubMedCrossRefGoogle Scholar
  39. 39.
    Taskiran C, Erdem O, Onan A, et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer. 2006;16:1789–93.PubMedCrossRefGoogle Scholar
  40. 40.
    Ding S, Li C, Lin S, et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol. 2006;37:861–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Erdem O, Taskiran C, Onan MA, et al. CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol. 2006;103:1007–11.PubMedCrossRefGoogle Scholar
  42. 42.
    Yao Y, Kubota T, Takeuchi H, et al. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology. 2005;25:201–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Yang LY, Lu WQ, Huang GW, et al. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer. 2006;6:110.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Saad RS, El-Gohary Y, Memari E, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol. 2005;36:955–61.PubMedCrossRefGoogle Scholar
  45. 45.
    Kyzas PA, Agnantis NJ, Stefanou D. Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch. 2006;448:768–75.PubMedCrossRefGoogle Scholar
  46. 46.
    Marioni G, Staffieri A, Manzato E, et al. Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol. 2006;126:633–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Dubinski W, Gabril M, Iakovlev VV, et al. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Hum Pathol. 2012;43:1037–43.PubMedCrossRefGoogle Scholar
  48. 48.
    Bockhorn M, Tsuzuki Y, Xu L, et al. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res. 2003;9:4221–6.PubMedGoogle Scholar
  49. 49.
    Davis DW, Inoue K, Dinney CP, et al. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res. 2004;64:4601–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Sennino B, Ishiguro-Oonuma T, Schriver BJ, et al. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 2013;73:3692–703.PubMedCrossRefGoogle Scholar
  51. 51.
    Anderberg C, Cunha SI, Zhai Z, et al. Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med. 2013;210:563–79.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–31.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Cunha SI, Pardali E, Thorikay M, et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med. 2010;207:85–100.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Matsuno F, Haruta Y, Kondo M, et al. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res. 1999;5:371–82.PubMedGoogle Scholar
  55. 55.
    Takahashi N, Haba A, Matsuno F, et al. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 2001;61:7846–54.PubMedGoogle Scholar
  56. 56.
    Tsujie M, Tsujie T, Toi H, et al. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer. 2008;122:2266–73.PubMedCrossRefGoogle Scholar
  57. 57.
    Uneda S, Toi H, Seon BK, et al. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer. 2009;125:1446–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Shen C, Kaelin Jr WG. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23:18–25.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Bussolati B, Bruno S, Grange C, et al. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 2008;22:3696–705.PubMedCrossRefGoogle Scholar
  60. 60.
    Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. the International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007;25:371–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Postiglione L, Di Domenico G, Caraglia M, et al. Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation. Int J Oncol. 2005;26:1193–201.PubMedGoogle Scholar
  63. 63.
    Pardali E, van der Schaft DW, Wiercinska E, et al. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene. 2011;30:334–45.PubMedCrossRefGoogle Scholar
  64. 64.
    Gromova P, Rubin BP, Thys A, et al. Endoglin/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours. J Cell Mol Med. 2012;16:306–17.PubMedCrossRefGoogle Scholar
  65. 65.
    Ciernik IF, Krayenbühl Ciernik BH, et al. Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi’s sarcoma. Clin Cancer Res. 1995;1:1119–24.PubMedGoogle Scholar
  66. 66.
    Ohta M, Tokuda Y, Kuge S, et al. A case of angiosarcoma of the breast. Jpn J Clin Oncol. 1997;27:91–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Morozov A, Downey RJ, Healey J, et al. Benign mesenchymal stromal cells in human sarcomas. Clin Cancer Res. 2010;16:5630–40.PubMedCrossRefGoogle Scholar
  68. 68.
    Royer-Pokora B, Busch M, Beier M, et al. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. Hum Mol Genet. 2010;19:1651–68.PubMedCrossRefGoogle Scholar
  69. 69.••
    Nolan-Stevaux O, Zhong W, Culp S, et al. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS One. 2012;7:12. This is a detailed study of the mechanism of action of TRC105.CrossRefGoogle Scholar
  70. 70.••
    Rosen LS, Hurwitz HI, Wong MK, et al. A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18:4820–9. This presents the results of the first-in-human study of TRC150 in advanced cancer patients.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Goff L, Cohen RB, Berlin J, et al. Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis. Paper presented at: ASCO annual meeting, Chicago, 2011.Google Scholar
  72. 72.
    Bendell JC, Gordon MS, Hurwitz H, et al. Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors. Paper presented at: ASCO annual meeting, Chicago, 2011.Google Scholar
  73. 73.
    Lui Y, Starr M, Pang H, et al. Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors. Paper presented at: ASCO annual meeting, Chicago, 2011.Google Scholar
  74. 74.
    Castonguay R, Werner ED, Matthews RG, et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem. 2011;286:30034–46.PubMedCrossRefGoogle Scholar
  75. 75.
    Karzai FH, Apollo A, Adelberg D, et al. A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC). Paper presented at: ASCO annual meeting, Chicago, 2012.Google Scholar
  76. 76.••
    Rosen LS, Robert FG, Matie D, et al. A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors. Paper presented at: ASCO annual meeting, Chicago, Jun 2013. This presented the results of the clinical trial combining TRC105 with bevacizumab. Google Scholar
  77. 77.
    Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Korn RL, Gordon MS, Rosen LS. Exploratory textural CT evaluation of the combination of TRC105 (anti-endoglin monoclonal antibody; MAb) and bevacizumab (BEV) indicates partial response by Choi criteria in BEV refractory advanced cancer patients (pts) and identifies candidate markers of response. Paper presented at: EORTC-AACR-NCI molecular targets meeting, Boston, 2013.Google Scholar
  79. 79.
    Hong H, Severin GW, Yang Y, et al. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2012;39:138–48.PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Muñoz R, Arias Y, Ferreras JM, et al. In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours. Cancer Immunol Immunother. 2013;62:541–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Lee S. Rosen
    • 1
    Email author
  • Michael S. Gordon
    • 2
  • Francisco Robert
    • 3
  • Daniela E. Matei
    • 4
  1. 1.Hematology-OncologyUCLA Medical Center Santa MonicaSanta MonicaUSA
  2. 2.Pinnacle Oncology HematologyScottsdaleUSA
  3. 3.Division of Hematology/OncologyUniversity of Alabama at BirminghamBirminghamUSA
  4. 4.Division of Hematology/OncologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations